Prasad Gabbita, PhD, Chief Executive Officer, has led the company in all aspects of preclinical drug discovery, development and biomarker assay programs at P2D Bioscience and its predecessor companies for the past ten years.  He brings 20 years of research experience and knowledge in neuroscience, toxicology, synthetic organic chemistry, drug formulation and delivery.  Prasad received his doctoral and post-doctoral training at the University of Kentucky College of Medicine and Sanders Brown Center on Aging in Lexington.  He has been the recipient of nearly $5.4 MM in research funding for drug and diagnostic development from several agencies including the Michael J. Fox Foundation, the Alzheimer’s Drug Discovery Foundation and the National Institutes of Health.  Prasad has authored about 20 peer-reviewed scientific publications and book chapters.
Floyd R Sallee MD, PhD, President, has previously led P2D’s CNS program (ADHD and Sleep disorders) as the Chief Medical Officer. He has held the C-suite position of Chief Medical Officer at Ironshore Pharmaceuticals Inc. for the last-five years; where he led the team which developed the currently marketed JornayPM involving patented Delexis formulation technology. Dr Sallee has over 30 years of experience in behavioral neuroscience with over 125 referred scientific publications.  Special knowledge and expertise in clinical pharmacology, attention deficit disorders, mood disorders, movement disorders and feeding/appetite disorders.  He also has extensive Phase I-II consultation experience with a range of clients from small to large Pharma with special expertise in Early Drug Development and Pipeline Assessment.
Matt Devalaraja, Chief Scientific Advisor and Board member has been associated with P2D for the last 4 years.  He is Founder, Chief Scientific Officer, and the Head of R&D of Corvidia Therapeutics, which was recently acquired by Novo Nordisk for $2.1B. Matt is an immunologist with over 20 years of experience in drug discovery and development across multiple therapeutic areas. Matt was Director of the Emerging Innovations Unit at AstraZeneca, where he enabled multiple clinical studies and developed the core hypothesis of precision cardiovascular therapeutics that formed the basis for the Corvidia spin out. Prior to that he was Head of Immunology Research, Pharmacokinetics, Clinical Pharmacology and Toxicology groups at Human Genome Sciences and has integral 3 BLA filings and two product approvals, Benlysta for Lupus and raxibacumab for Anthrax. Matt started his career at Pfizer, Ann Arbor and brought forth their first biologic program for the Pfizer Global Immunology portfolio. Subsequently, he moved up the ranks and became the Head of Biologics Discovery for the Ann Arbor site where he was responsible for multiple therapeutic areas including immunology, cardiovascular, dermatology and anti-infective diseases. He is currently on the Board of AUM Biosciences and is founder of two other startups. Matt received his Ph.D. from University of Kentucky and Post-Doctoral training at Vanderbilt University.